PRODUCTS AND SERVICES
Cell Extraction Medium and AdiLight-2 Photo Activation Device
Technology
Photo-Activated ASC/PRP and Lecithin
Description
Vials of Lecithin and AdiLIght-2 Units sold to MediVet under the Exclusive Master Distribution Agreement.
See: http://www.medivetbiologics.com/
Commercialisation Strategy
Continue sale and supply through existing distribution channels and support systems.
Status
Commercialized – Active Account-exploring possible collaborations on other Company Products.
Technology
Animal PBD-PSC (PRIMOSTEM CPS) Small Kits-for use in conjunction with Authorized Laboratory processing of submitted blood.
Description
PRIMOSTEM CPS – In clinic small blood draw kits and shipping materials for drawing and submission of peripheral blood to Tithon’s Authorized Laboratory for processing and harvesting PSC using PBD-PSC Technology for therapeutic applications of PBD-PSC requiring small animal blood quantities e.g. dogs or cats.
Commercialisation Strategy
Clinical Studies by Innovators and Early Adopters — followed by full commercialization through existing distribution networks lead by prominent practitioner(s).
Status
Small Kits being provided to Veterinarian clinics for testing, utilizing Tithon’s Authorized Laboratory .
Technology
Animal PBD-PSC (PRIMOSTEM CPS) Large Kits-for use in conjunction with Authorized Laboratory processing of submitted blood.
Description
PRIMOSTEM CPS – In clinic large blood draw kits and shipping materials for drawing and submission of peripheral blood to Tithon’s Authorized Laboratory for processing and harvesting PSC using PBD-PSC Technology for therapeutic applications of PBD-PSC requiring larger blood quantities e.g. equine.
Commercialisation Strategy
Clinical Studies by Innovators and Early Adopters — followed by full commercialization through existing distribution networks lead by prominent practitioner(s).
Status
Large Kits being provided to Veterinarian clinics for testing, utilizing Tithon’s Authorized Laboratory .
.
Antigen-Specific Immunotherapy
Technology
Antigen-Specific Immunotherapy Technology
Description
Live animal tissue processed into isopathic sarcodes and registered with the US FDA for addressing various animal autoimmune conditions.
K9 DeSense - D
Commercialisation Strategy
Marketing and sale through both Veterinarian clinics and over the counter through a purpose built web site.
Status
The initial formulation intended to address canine type 1 diabetes is currently being formulated and registered with the U.S. Food and Drug Administration.